CoChat

Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Background Oral acetylcysteine (also known as N-acetylcysteine) is used with pirfenidone to treat idiopathic pulmonary fibrosis (IPF) in Europe. However, no randomised studies have investigated the safety and tolerability of this combination. The PANORAMA study assessed the safety and tolerability of acetylcysteine combined with pirfenidone in patients with IPF. Exploratory efficacy endpoints were also assessed. Methods We did a double-blind randomised trial at 48 sites in eight countries. Patients with IPF aged 40-80 years and established on pirfenidone (at least 1602 mg/day for 8 weeks or longer) were randomly assigned in a 1:1 ratio by interactive voice response system to receive concomitant oral acetylcysteine (600 mg, three times daily) or placebo for 24 weeks. A stratified blocked randomisation scheme was used with a block size of 4. Randomisation was stratified by dose of pirfenidone (2403 mg/day [the maximum dose] or Findings 123 patients participated in the study between June 28, 2013, and Feb 24, 2015. 61 were assigned to the acetylcysteine group (60 received study medication and included in analysis) and 62 were assigned to the placebo group (all included in analysis). The occurrence of at least one adverse event (46 [77%] patients receiving acetylcysteine vs 50 [81%] receiving placebo), adverse events related to study treatment (17 [28%] vs 16 [26%]), and the number of patients experiencing severe adverse events (three [5%] vs two [3%]), life-threatening adverse e…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(16)30044-3

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Cited by

See all 146

Metadata

Authors
Behr, J., Bendstrup, E., Crestani, B., Günther, A., Olschewski, H., Sköld, C. M., Wells, A., Wuyts, W., Koschel, D., Kreuter, M., Wallaert, B., Lin, C.-Y., Beck, J., & Albera, C.
Affiliations
  • Asklepios Fachkliniken München-Gauting (DE)
  • Aarhus University Hospital (DK)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • Justus-Liebig-Universität Gießen (DE)
  • Medical University of Graz (AT)
  • Karolinska University Hospital (SE)
  • Royal Brompton & Harefield NHS Foundation Trust (GB)
  • Universitair Ziekenhuis Leuven (BE)
  • Heidelberg University (DE)
  • Centre Hospitalier Universitaire de Lille (FR)
  • Genentech (US)
  • University of Turin (IT)
Corresponding author
Behr, Jürgen
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2016-06
Volume
4
Issue
6
Pages
445-453
ISSN
2213-2600 (ISSN-L)
OpenAlex
W2346218824
Cited by
146
References
21
Citations by year
2026: 6 · 2025: 7 · 2024: 23 · 2023: 6 · 2022: 11 · 2021: 11 · 2020: 16 · 2019: 18 · 2018: 17 · 2017: 20 · 2016: 11
FWCI
19.97
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Respiratory Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • Lirias (submittedVersion)
Funders
  • National Institute for Health and Care Research
  • Imperial College London
  • Roche
  • Royal Brompton and Harefield NHS Foundation Trust
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
idiopathic pulmonary fibrosis, N-acetylcysteine, pirfenidone, combination therapy, drug safety, tolerability, adverse events, forced vital capacity, diffusing capacity for carbon monoxide, 6-minute walk distance, lung function, antifibrotic therapy
MeSH terms
Acetylcysteine, Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Double-Blind Method, Drug Therapy, Combination, Europe, Expectorants, Female, Humans, Male, Middle Aged, Pyridones, Treatment Outcome, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. https://app.cochat.ai/papers/10.1016/s2213-2600(16)30044-3
The paper
Behr, J., Bendstrup, E., Crestani, B., Günther, A., Olschewski, H., Sköld, C. M., Wells, A., Wuyts, W., Koschel, D., Kreuter, M., Wallaert, B., Lin, C.-Y., Beck, J., & Albera, C. (2016). Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(16)30044-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.